Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 3
2022 4
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Did you mean mittal k[au] (557 results)?
Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.
Sabatino JJ Jr, Mittl K, Rowles WM, McPolin K, Rajan JV, Laurie MT, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander JR, DeRisi JL, Hollenbach JA, Wilson MR, Zamvil SS, Bove R. Sabatino JJ Jr, et al. Among authors: mittl k. JCI Insight. 2022 Feb 22;7(4):e156978. doi: 10.1172/jci.insight.156978. JCI Insight. 2022. PMID: 35030101 Free PMC article.
SARS-CoV-2 Variant Exposures Elicit Antibody Responses With Differential Cross-Neutralization of Established and Emerging Strains Including Delta and Omicron.
Laurie MT, Liu J, Sunshine S, Peng J, Black D, Mitchell AM, Mann SA, Pilarowski G, Zorn KC, Rubio L, Bravo S, Marquez C, Sabatino JJ, Mittl K, Petersen M, Havlir D, DeRisi J. Laurie MT, et al. Among authors: mittl k. J Infect Dis. 2022 Jun 1;225(11):1909-1914. doi: 10.1093/infdis/jiab635. J Infect Dis. 2022. PMID: 34979030 Free PMC article.
Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity.
Sabatino JJ Jr, Mittl K, Rowles W, Mcpolin K, Rajan JV, Zamecnik CR, Dandekar R, Alvarenga BD, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Augusto DG, Alexander J, Hollenbach JA, Wilson MR, Zamvil SS, Bove R. Sabatino JJ Jr, et al. Among authors: mittl k. medRxiv. 2021 Sep 20:2021.09.10.21262933. doi: 10.1101/2021.09.10.21262933. Preprint. medRxiv. 2021. PMID: 34580672 Free PMC article. Updated.
Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis.
Novak F, Nilsson AC, Nielsen C, Holm DK, Østergaard K, Bystrup A, Byg KE, Johansen IS, Mittl K, Rowles W, Mcpolin K, Spencer C, Sagan S, Gerungan C, Wilson MR, Zamvil SS, Bove R, Sabatino JJ, Sejbaek T. Novak F, et al. Among authors: mittl k. Mult Scler Relat Disord. 2021 Nov;56:103251. doi: 10.1016/j.msard.2021.103251. Epub 2021 Sep 9. Mult Scler Relat Disord. 2021. PMID: 34571415 Free PMC article.
SARS-CoV-2 variant exposures elicit antibody responses with differential cross-neutralization of established and emerging strains including Delta and Omicron.
Laurie MT, Liu J, Sunshine S, Peng J, Black D, Mitchell AM, Mann SA, Pilarowski G, Zorn KC, Rubio L, Bravo S, Marquez C, Sabatino JJ Jr, Mittl K, Petersen M, Havlir D, DeRisi J. Laurie MT, et al. Among authors: mittl k. medRxiv. 2021 Dec 22:2021.09.08.21263095. doi: 10.1101/2021.09.08.21263095. Preprint. medRxiv. 2021. PMID: 34981075 Free PMC article. Updated.
Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators.
Sabatino JJ Jr, Mittl K, Rowles W, Zamecnik CR, Loudermilk RP, Gerungan C, Spencer CM, Sagan SA, Alexander J, Mcpolin K, Chen P, Deshpande C, Wyse K, Maiese EM, Wilson MR, Zamvil SS, Bove R. Sabatino JJ Jr, et al. Among authors: mittl k. Mult Scler Relat Disord. 2022 Dec 28;70:104484. doi: 10.1016/j.msard.2022.104484. Online ahead of print. Mult Scler Relat Disord. 2022. PMID: 36608538 Free PMC article.
Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients.
Bajwa HM, Novak F, Nilsson AC, Nielsen C, Holm DK, Østergaard K, Witt AH, Byg KE, Johansen IS, Mittl K, Rowles W, Zamvil SS, Bove R, Sabatino JJ, Sejbaek T. Bajwa HM, et al. Among authors: mittl k. Mult Scler Relat Disord. 2022 Apr;60:103729. doi: 10.1016/j.msard.2022.103729. Epub 2022 Mar 6. Mult Scler Relat Disord. 2022. PMID: 35334278 Free PMC article.